Five Competitors Confirmed On Canadian Adalimumab

Amgen, Fresenius, Merck And Viatris Confirm Further Launches Of Humira Biosimilars

Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.

Canada Boxing Gloves Boxer Fight
Multiple biosimilars to adalimumab are duking it out in Canada • Source: Shutterstock

Four further Canadian competitors on Humira (adalimumab) have confirmed launch alongside Sandoz, opening the market up to immediate multi-source competition from five biosimilars to the world’s biggest-selling medicine.

Viatris has announced the launch of its Hulio version – licensed from Fujifilm Kyowa Kirin Biologics – while Merck Canada...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.